Do the incentives in 3-tier pharmaceutical benefit plans operate as intended? Results from a physician leadership survey

American Journal of Managed Care

Volumn 11, Issue 1, 2005, Pages 16-22

  Shrank, William H ^a,f   Young, Henry N ^b   Ettner, Susan L ^d   Glassman, Peter ^a,d,e   Asch, Steven M ^a,d,e   Kravitz, Richard L ^b,c  

^a Div of General Internal Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RAND CORPORATION   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AWARENESS; CONTROLLED STUDY; DOCTOR PATIENT RELATION; DRUG COST; DRUG FORMULARY; FEMALE; HEALTH CARE SYSTEM; HUMAN; HUMAN EXPERIMENT; LEADERSHIP; MALE; NORMAL HUMAN; PATIENT CARE; PHARMACIST; PHARMACY BENEFIT MANAGER; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RESPONSIBILITY; REVIEW;

DATA COLLECTION; DEDUCTIBLES AND COINSURANCE; FEMALE; FINANCING, PERSONAL; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; INTERPROFESSIONAL RELATIONS; LEADERSHIP; MALE; MIDDLE AGED; MOTIVATION; PHARMACISTS; PHYSICIANS; UNITED STATES;

EID: 12144285234     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Curtiss FR. Perspectives: drugs, PPOs, tiered cost share for beneficiaries and consumer preferences. J Manag Care Pharm. 2002;8(3):177-180.
2. William M. Mercer, Incorporated. Prescription Drug Coverage and Formulary Use in California: Differing Approaches and Emerging Trends. Oakland, Calif: California HealthCare Foundation; May 2001. Available at: http://www.pharmacy. ca.gov/pdfs/pbm_chcf_rx.pdf. Accessed February 20, 2004.
3. Kaiser Family Foundation and Health Research and Educational Trust. Employer health benefits: 2002 summary of findings. Available at: http://www.kff.org/insurance/3252-index.cfm. Accessed November 18, 2003.
4. Kaiser Family Foundation and Health Research and Educational Trust. Employer health benefits: 2002 annual survey. Available at: http://www. kaisernetwork.org/health_cast/uploaded_files/ACF4D93.pdf. Accessed December 2, 2003.
5. Medical Expenditure Panel Survey Highlights. Distribution of Healthcare Expenses, 1996. Rockville, Md: Agency for Healthcare Research and Quality; May 2000. AHRQ publication 00-0024. Available at: http://www.meps.ahrq.gov/papers/ hl11_00-0024/hl11.pdf. Accessed October 19, 2004.
6. Rector TS, Finch MD, Danzon PM, Pauly MV, Manda BS. Effect of tiered prescription copayments on the use of preferred brand medications. Med Care. 2003;41:398-406.
7. Nair KV, Wolfe P, Valuck RJ, McCollum MM, Ganther JM, Lewis SJ. Effects of a 3-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease. J Manag Care Pharm. 2003;9:123-133.
8. Briesacher B, Kamal-Bahl S, Hochberg M, Orwig D, Kahler KH. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2004;164:1679-1684.
9. Motheral B, Fairman, KA. Effect of a three-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39:1293-1304.
10. Joyce CF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs [published correction appears in JAMA. 2002;288:2409]. JAMA. 2002;288:1733-1739.
11. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349:2224-2232.
12. Shrank WH. Effect of incentive-based formularies on drug utilization and spending [letter]. N Engl J Med. 2004;350:1057.
13. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002;346:822-829.
14. Strunk BC, Reschovsky JD. Kinder and gentler: physicians and managed care, 1997-2001. Washington, DC: Center for Studying Health System Change. Tracking Report No. 5, November 2002. Available at: http://www.hschange.com/ CONTENT/486/?topic=topic03. Accessed August 9, 2004.
15. Shrank WH, Ettner SL, Glassman P, Asch S. A bitter pill: formulary variability and the challenge for prescribing physicians. J Am Board Fam Pract. 2004;17:401-407.
16. Pasko T, SMart DR. Physician Characteristics and Distribution in the US, 2003-2004. Chicago, III: American Medical Association; 2002.
17. Oregon Health & Science University. Drug effectiveness review project. Available at: http://www.ohsu.edu/drugeffectiveness/reports/index.htm. Accessed August 12, 2004.
18. Hillman AL, Pauly MV, Escarce JJ, et al. Financial incentives and drug spending in managed care. Health Aff (Millwood). 1999;18(2):189-200.
19. Stuart B, Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 1999;18(2):201-212.
20. Smith DG. The effects of copayments and generic substitution on the use and costs of prescription drugs. Inquiry. 1993;30:189-198.
21. Reeder CE, Nelson AA. The differential impact of copayment on drug use in a Medicaid population. Inquiry. 1985;22:396-403.
22. Harris BL, Stergachis A, Reid LD. The effect of drug co-payments on utilization and cost of pharmaceuticals in a health maintenance organization. Med Care. 1990;28:907-917.
23. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291:2344-2350.
24. Alexander GC, Casalino LP, Tseng CW, McFadden D, Meltzer DO. Barriers to patient-physician communication about out-of-pocket costs. J Gen Intern Med. 2004;19:856-860.
25. Brennan TA, Lee TH. Allergic to generics. Ann Intern Med. 2004;141:126-130.
26. Johnson RE, Goodman MJ, Hornbrook MC, Eldredge MB. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care. 1997;35:1119-1131.
27. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285:421-429.
28. Doherty RB. Assessing the new Medicare prescription drug law. Ann Intern Med. 2004;141:391-395.
29. Stagnitti MN, Miller GE, Moeller IF. Outpatient prescription drug expenses, 1999. Rockville, Md: Agency for Healthcare Research and Quality; 2003. MEPS Chartbook No. 12. AHRQ Pub. No. 04-0001. Available at: http://www.meps.ahrq.gov/Papers/CB12_04-0001/CB12.pdf. Accessed December 1, 2004.
30. Corley ST. Electronic prescribing: a review of costs and benefits. Top Health Inf Manage. 2003;24:29-38.
31. Landon BC, Reschovsky JD, Blumenthal D. Physicians' views of formularies: implications for Medicare drug benefit design. Health Aff (Millwood). 2004;23(1):218-226.
32. Huskamp HA, Epstein AM, Blumenthal D. The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare? Health Aff (Millwood). 2003 May-Jun;22(3):149-158.